
Patrick C Ma MD MSc
Thoracic Cancer
Frank and Franco Endowed Professor of Medicine-Hematology/Oncology, and Molecular & Precision Medicine, Interim Division Chief of Hematology/Oncology, Associate Director of Translational Research, Thoracic Oncology Multidisciplinary Disease Team Leader, Co-leader of Next Generation Therapies Program
Join to View Full Profile
Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center500 University Drive, P.O. Box 850, Mail Code CH46Hershey, PA 17033
Phone+1 717-531-8870
Fax+1 717-531-5076
Dr. Ma is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Patrick Ma is a highly experienced oncologist based in Hershey, PA. Specializing in Thoracic Cancer, Dr. Ma completed his education and fellowships across prestigious institutions such as Dana-Farber Cancer Institute and Tufts Medical Center, among others. He currently serves as Interim Division Chief of Hematology/Oncology, and the Associate Director of Translational Research at Penn State Cancer Institute and Endowed Professor at Penn State Milton S. Hershey Medical Center, Penn State College of Medicine. His notable past roles include Director of Aerodigestive Oncology Translational Research at Cleveland Clinic Taussig Cancer Institute and leading the lung cancer program at WVU Medicine. Dr. Ma is also nationally and internationally renowned in his clinical and translational research work. His research work has been widely published and he's a part of many oncology clinical trials. Recognized for his contribution in the field, he was named Best Doctors (Medical Oncology) by Cleveland Magazine in 2013-2014. His outstanding patient care quality was recognized by a Press Ganey Top Clinician Award as a top 2 percentile performing faculty at the WVU Medicine, WVU Cancer Institute, Morgantown, WV. At Penn State College of Medicine, Dr. Ma was recognized with a 2024-25 Research & Innovation Award - Career Citation Recognition Award for his research achievements throughout his career as a clinician-scientist in medical oncology.
Education & Training
Dana-Farber Cancer InstituteFellowship, Thoracic Oncology Research, 2001 - 2003
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
St Elizabeth's Medical CenterResidency, Internal Medicine, 1996 - 1999
Toronto General HospitalResidency, Family Medicine, C.C.F.P., 1994 - 1996
University of Toronto Faculty of MedicineClass of 1994
Certifications & Licensure
LA State Medical License 2025 - 2026
PA State Medical License 2019 - 2026
WV State Medical License 2015 - 2021
OH State Medical License 2005 - 2016
IL State Medical License 2003 - 2005
MA State Medical License 1996 - 2005
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Career Citation Milestone Award - 2025 Research & Innovation Awards Penn State College of Medicine, Penn State University, 2025
- Castle Connolly - Top Doctor: Medical Oncology Susquehanna Style magazine, 2025
- Caris Precision Oncology Alliance (POA) Chair Leadership Award Caris Life Science, 2023
Clinical Trials
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Start of enrollment: 2016 Apr 10
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Publications & Presentations
PubMed
- SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.Jennifer A Marks, Kieran Sweeney, Andrew Elliott, Brinda Gupta, Ari VanderWalde
Lung Cancer. 2026-01-10 - 1 citationsIntegrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.Amin H Nassar, Chul Kim, Tolulope Adeyelu, Elias Bou Farhat, Hassan Abushukair
Nature Communications. 2025-08-19 - CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 () Fusions.Tejas Patil, Jessica J Lin, Parneet K Cheema, Daniel R Carrizosa, Mark E Burkard
JCO Precision Oncology. 2025-08-01
Lectures
- Novel Platforms and Clinical Applications for Noninvasive Molecular Testing2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
- PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Penn State Cancer Institute Joins Caris Life Sciences' Precision Oncology AllianceAugust 25th, 2020
‘Cancer-Agnostic’ NTRK Inhibitor Approval Ushers in Paradigm of Personalized Genomics-Guided TherapeuticsJanuary 10th, 2019
Mesothelioma Clinical Trial Opens with High ExpectationsJune 16th, 2017
Grant Support
- Studies Of Alternations Of C-MET In SCLCNational Cancer Institute2005–2009
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin), Chinese (Cantonese)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









